CCHT(SZ:000661)2024-08-16 09:05Financial Performance - The company achieved operating revenue of 6.639 billion CNY, an increase of 7.63% compared to the same period last year [2] - Net profit attributable to shareholders decreased by 20.40% to 1.720 billion CNY [2] - Subsidiary JinSai Pharmaceutical generated revenue of 5.152 billion CNY, a growth of 0.25%, with net profit down by 19.49% to 1.769 billion CNY [2] - Subsidiary BaiKe Bio reported revenue of 618 million CNY, up 10.50%, and net profit increased by 23.54% to 138 million CNY [2] - Subsidiary HuaKang Pharmaceutical's revenue rose by 10.37% to 391 million CNY, with net profit up 26.42% to 24 million CNY [2] - High-tech Real Estate subsidiary saw revenue increase by 372.45% to 456 million CNY, with net profit soaring by 533.17% to 33 million CNY [2] Research and Development - R&D investment reached 1.138 billion CNY, a year-on-year increase of 10.18%, with R&D expenses at 887 million CNY, up 26.16% [2] - The company is advancing new product development, with several products receiving registration certificates and applications being accepted [2][4] Sales and Marketing - Sales expenses totaled 1.933 billion CNY, a growth of 9.38% [2] - Management expenses increased by 53.71% to 551 million CNY due to changes in management structure and responsibilities [2] International Expansion - The company accelerated international sales of growth hormone products, achieving sales revenue of 85.238 million CNY, a significant increase of 267.78% [3] - Efforts are being made to establish overseas sales channels and partnerships [3] Real Estate Operations - The real estate segment implemented targeted marketing strategies, reducing inventory by approximately 400 million CNY [3] Future Plans and Shareholder Returns - The company has developed a three-year shareholder return plan (2023-2025) and is exploring ways to enhance shareholder returns [4]